Abstract
Simple SummaryThe immune system plays an important role in the development and progression of cancer. The current treatments for ovarian cancer (surgery and chemotherapy) create changes in the immune system, but it is not clear how. Nevertheless, if immunotherapy is associated on top of this, then it seems crucial to understand what is changing in the current state of the art. In this study, we measured immune-related proteins in the serum of ovarian cancer patients throughout their treatment. We discovered that carboplatin–paclitaxel as a chemotherapeutic treatment reduces immunosuppression and promotes immunostimulation, meaning that the immune system be-comes less hostile and more in favour of the patient. Therefore, chemotherapy seems to induce a temporary window of opportunity to insert immunotherapy during the current treatment of ovarian cancer patients.In monotherapy, immunotherapy has a poor success rate in ovarian cancer. Upgrading to a successful combinatorial immunotherapy treatment implies knowledge of the immune changes that are induced by chemotherapy and surgery. Methodology: Patients with a new ovarian cancer diagnosis underwent longitudinal blood samples at different time points during primary treatment. Results.: Ninety patients were included in the study (33% primary debulking surgery (PDS) with adjuvant chemotherapy (ACT), 61% neo-adjuvant chemotherapy (NACT) with interval debulking surgery (IDS), and 6% debulking surgery only). Reductions in immunosuppression were observed after NACT, but surgery reverted this effect. The immune-related proteins showed a pronounced decrease in immune stimulation and immunosuppression when primary treatment was completed. NACT with IDS leads to a transient amelioration of the immune microenvironment compared to PDS with ACT. Conclusion: The implementation of immunotherapy in the primary treatment schedule of ovarian cancer cannot be induced blindly. Carboplatin–paclitaxel seems to ameliorate the hostile immune microenvironment in ovarian cancer, which is less pronounced at the end of primary treatment. This prospective study during primary therapy for ovarian cancer that also looks at the evolution of immune-related proteins provides us with an insight into the temporary windows of opportunity in which to introduce immunotherapy during primary treatment.
Highlights
Ovarian cancer is the 8th most commonly diagnosed cancer among females and the8th most frequent cause of female cancer-related deaths worldwide [1]
Chemotherapy was administered in 85 patients, and in 61%, chemotherapy was administered in an upfront neoadjuvant setting
Five patients (6%) received no Cancers 2021, 13, 5899 chemotherapy based on their FIGO stage and histology
Summary
Ovarian cancer is the 8th most commonly diagnosed cancer among females and the8th most frequent cause of female cancer-related deaths worldwide [1]. Ovarian cancer is the 8th most commonly diagnosed cancer among females and the. Most ovarian cancer patients are diagnosed in an advanced stage (FIGO stage III-IV) and have a significantly lower 5-year survival rate compared to stage I ovarian cancer (93.3 (95% CI 91.6–95.0%) versus 26.9% (95% CI 25.3–28.6%)) [2]. It remains the most relevant protein that can be used to discriminate between benign and malignant disease at diagnosis [12], it is still a non-specific protein for ovarian cancer. Increased CA125 levels are observed in benign diseases (e.g., endometriosis, pelvic inflammatory disease, pregnancy, and ovarian cysts) and nongynaecological malignancies (e.g., breast, lung, colon, and pancreatic cancer) [13,14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
